T-Type Ca2+ channel blockade prevents sudden death in mice with heart failure

Circulation

Volumn 120, Issue 9, 2009, Pages 743-752

  Kinoshita, Hideyuki ^c   Kuwahara, Koichire ^c   Takano, Makoto ^a   Arai, Yuji ^b   Kuwabara, Yoshihiro ^c   Yasuno, Shinji ^c   Nakagawa, Yasuaki ^c   Nakanishi, Michio ^c   Harada, Masaki ^c   Fujiwara, Masataka ^c   Murakami, Masao ^c   Ueshima, Kenji ^c   Nakao, Kazuwa ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Arrhythmia; Autonomic; Calcium; Heart failure; Ion channels; Nervous system

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; EFONIDIPINE; MIBEFRADIL; NITRENDIPINE; DIHYDROPYRIDINE DERIVATIVE; NITROPHENOL; ORGANOPHOSPHORUS COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CELL MEMBRANE DEPOLARIZATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; MEMBRANE STEADY POTENTIAL; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL; TRANSGENIC MOUSE; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE CELL; METABOLISM; MORTALITY; PATCH CLAMP; PHYSIOLOGY;

ANIMALS; ARRHYTHMIAS, CARDIAC; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; FEMALE; MIBEFRADIL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NITRENDIPINE; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PATCH-CLAMP TECHNIQUES;

EID: 70349324478     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.857011     Document Type: Article

References (47)

1. Tomaselli GF, Marbán. E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42:270-283. (Pubitemid 29243156)
2. 2+ channels and heart failure. Proc Assoc. Am Physicians. 1999;111:429-437.
3. 2+ channels in the heart. Cell Calcium. 2006;40:205-220.
4. 2+ channels in fetal and diseased, heart. J Pharmacol Sci. 2005;99:205-210.
5. 2+ channel in murine hearts during the embryonic period. Am J Physiol Heart Circ Physiol. 2004;286:H2257-H2263.
6. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 1993;73:777-782.
7. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res. 1994;75:149-155.
8. Martinez ML, Heredia MP, Delgado C. Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol. 1999;31:1617-1625.
9. Chiang CS, Huang CH, Chieng H, Chang YT, Chang D, Chen JJ, Chen YC, Chen YH, Shin HS, Campbell KP, Chen CC. The Ca (v) 3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice. Circ Res. 2009;104:522-530.
10. Villame J, Massicotte J, Jasmin G, Dumont L. Effects of mibefradil, a T-and L-type calcium, channel blocker, on cardiac remodeling in the UM-X7.1 cardiomyopathic hamster. Cardiovasc Drugs Ther. 2001; 15: 41-48.
11. Sandmann S, Min JY, Meissner A, Unger T. Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats. Cardiovasc Res. 1999;44:67-80.
12. Mulder P, Richard V, Compagnon P, Henry JP, Lallemand F, Clozel JP, Koen R, Mace B, Thuillez C. Increased survival after long-term treatment with, mibefradil, a selective T-channel calcium, antagonist, in heart failure. J Am Coll. Cardiol. 1997;29:416-421. (Pubitemid 27059975)
13. Kuwahara K, Saito Y, Ogawa E, Takahashi N, Nakagawa Y, Naruse Y, Harada M, Hamanaka I, Izumi T, Miyamoto Y, Kishimoto I, Kawakami R, Nakanishi M, Mori N, Nakao K. The neuron-restrictive silencer element-neuron-restrictive silencer factor system regulates basal and endothelin 1-inducible atrial natriuretic peptide gene expression in ventricular myocytes. Mol Cell Biol. 2001;21:2085-2097. (Pubitemid 32479630)
14. Kuwahara K, Saito Y, Takano M, Arai Y, Yasuno S, Nakagawa Y, Takahashi N, Adachi Y, Takemura G, Horie M, Miyamoto Y, Morisaki T, Kuratomi S, Noma A, Fujiwara H, Yoshimasa Y, Kinoshita H, Kawakami R, Kishimoto I, Nakanishi M, Usami S, Saito Y, Harada M, Nakao K. NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function. EMBO J. 2003;22:6310-6321. (Pubitemid 37522588)
15. 2+ currents by efonidipine: possible mechanism for its chronottopic effect. Eur J Pharmacol. 1998;349:351-357.
16. 2+ channel blockers. Life Sci. 2008;82:554-560.
17. Tanaka H, Komikado C, Shimada H, Takeda K, Namekata I, Kawanishi T, Shigenobu K. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J Pharmacol Sci. 2004;96:499-501. (Pubitemid 40144072)
18. 2+ channels. Br J Pharmacol. 2004; 143:1050-1057.
19. Jinnah HA, Yitta S, Drew T, Kim BS, Visser JE, Rothstein JD. Calcium channel activation and self-biting in mice. Proc Natl Acad Sci USA. 1999;96:15228-15232.
20. Shudo C, Masuda Y, Sugita H, Tamura T, Furukawa S, Hayashi K, Hirata H, Shikada K, Tanaka S, Tomita K. Effects of efonidipine, nicardipine and Captopril on proteinuria in aged spontaneously hypertensive rats. Arzneimittelforschung. 1996;46:852-854.
21. 2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol. 2005;45:241-246.
22. 2+ channel alpha 1-subunits and a novel spliced variant of the alphalC-subunit in rat ductus arteriosus. Am J Physiol Heart Circ Physiol. 2006;290:H1660-H1670.
23. Kawakami R, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Nakagawa Y, Nakanishi M, Tanimoto K, Usami S, Yasuno S, Kinoshita H, Chusho H, Tamura N, Ogawa Y, Nakao K. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation. 2004;110:3306-3312. (Pubitemid 39557492)
24. Shioya T. A simple technique for isolating healthy heart cells from mouse models. J Physiol Sci. 2007;57:327-335.
25. Gehrmann J, Berul CI. Cardiac electrophysiology in genetically engineered mice. J Cardiovasc Electrophysiol. 2000;11:354-368.
26. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain, natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-1412.
27. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain, natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-1287.
28. 28. Leuranguer V, Mangoni ME, Nargeot J, Richard S. Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects. J Cardiovasc Pharmacol. 2001; 37:649-661. (Pubitemid 32480433)
29. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93:1043-1065.
30. Guzzetti S, Cogliati C, Turiel M, Crema C, Lombardi F, Malliani A. Sympathetic predominance followed by functional denervation in the progression of chronic heart failure. Eur Heart J. 1995;16:1100-1107.
31. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG, Traversi E, Cobelli F. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003; 107: 565-570. (Pubitemid 36176805)
32. Sandercock GR, Brodie DA. The role of heart rate variability in prognosis for different modes of death in chronic heart failure. Pacing Clin Electrophysiol. 2006;29:892-904.
33. Carbone E, Giancippoli A, Marcantoni A, Guido D, Carabelli V. A new role for T-type channels in fast "low-threshold" exocytosis. Cell Calcium. 2006;40:147-154.
34. Pellizzer AM, Kamen PW, Esler MD, Lim S, Krum H. Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension. J Hypertens. 2001;19:279-285. (Pubitemid 32116279)
35. Harada K, Nomura M, Nishikado A, Uehara K, Nakaya Y, Ito S. Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. Circ J. 2003;67:139-145.
36. Just A, Faulhaber J, Ehmke H. Autonomic cardiovascular control in conscious mice. Am. J Physiol Regul Integr Comp Physiol. 2000;279: R2214-R2221.
37. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415: 198-205.
38. 2+ release contributes to automaticity in cat atrial pacemaker cells. J Physiol. 2000;524(part 2):415-422.
39. Sandmann S, Bohle RM, Dreyer T, Unger T. The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats. Virchows Arch. 2000;436:147-157.
40. Su W, Quo Z, Randall DC, Cassis L, Brown DR, Gong MC. Hypertension, and disrupted blood pressure circadian rhythm in type 2 diabetic db/db mice. Am. J Physiol Heart Circ Physiol. 2008;295:H1634-H1641.
41. K1 in rat ventricular cells: a novel paradigm for arrhythmia in heart failure? Cardiovasc Res. 2005;68:204-212.
42. Dong D, Duan Y, Guo J, Roach DE, Swirp SL, Wang L, Lees-Miller JP, Sheldon. RS, Molkentin JD, Duff HJ. Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels. Cardiovasc Res. 2003;57:320-332. (Pubitemid 36144211)
43. Khoo MS, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, Grueter CE, Guan X, Oddis CV, Zhang R, Mendes L, Ni G, Madu EC, Yang J, Bass M, Gomez RJ, Wadzinski BE, Olson EN, Colbran RJ, Anderson ME. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation. 2006; 114: 1352-1359. (Pubitemid 44454555)
44. Anderson KP. Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. Ann. Noninvasive Electrocardiol. 2003;8:75-89. (Pubitemid 38569956)
45. Minami J, Ishimitsu T, Kawano Y, Matsuoka H. Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol. 1998;25:572-576. (Pubitemid 28321624)
46. Ewing DJ. Heart rate variability: an important new risk factor in patients following myocardial infarction. Clin Cardiol. 1991;14:683-685.
47. Weiss JN, Nademanee K, Stevenson WG, Singh B. Ventticular arrhythmias in ischemic heart disease. Ann Intern. Med. 1991;114:784-797.